Board elects new CEO to molecular diagnostics company SIRS-Lab GmbH
Barbara Staehelin: “The SIRS-Lab team is an impressive group, and I believe the SIRS-Lab technology has the potential to unlock this challenging diagnostic field by industry partnerships and with its own product pipeline.”
Nicolas Fulpius and Katrin Uschmann, Board members, comment: “We are very pleased to have recruited Mrs. Staehelin. She has unmatched experience and competences to lead an innovative company like SIRS-Lab to the next level of its development.”
Other news from the department people
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.